Could a malaria drug and a transplant drug keep breast cancer from returning?
NCT ID NCT03032406
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This pilot trial investigates whether hydroxychloroquine (a malaria drug) and everolimus (an immune-suppressing drug), taken alone or together, can help prevent breast cancer from returning in high-risk patients. The study enrolls people who have completed primary treatment for stage IIB breast cancer but still have cancer cells in their bone marrow. The main goal is to see if the treatment is safe and tolerable enough to continue testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hydroxychloroquine and everolimus
- What this could lead to
- If successful, this approach could point toward a new strategy to prevent breast cancer from coming back in patients who have completed initial treatment.
- What could go wrong
- This is a small, early-phase pilot trial focused on feasibility and safety, not effectiveness. The drugs may cause side effects, and the COVID-19 pandemic disrupted enrollment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IIB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.